Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Glioblastoma | Primary research

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Authors: Wei-cheng Lu, Hui Xie, Ce Yuan, Jin-jiang Li, Zhao-yang Li, An-hua Wu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background and aims

Glioblastoma (GBM) is a common and aggressive primary brain tumor, and the prognosis for GBM patients remains poor. This study aimed to identify the key genes associated with the development of GBM and provide new diagnostic and therapies for GBM.

Methods

Three microarray datasets (GSE111260, GSE103227, and GSE104267) were selected from Gene Expression Omnibus (GEO) database for integrated analysis. The differential expressed genes (DEGs) between GBM and normal tissues were identified. Then, prognosis-related DEGs were screened by survival analysis, followed by functional enrichment analysis. The protein–protein interaction (PPI) network was constructed to explore the hub genes associated with GBM. The mRNA and protein expression levels of hub genes were respectively validated in silico using The Cancer Genome Atlas (TCGA) and Human Protein Atlas (HPA) databases. Subsequently, the small molecule drugs of GBM were predicted by using Connectivity Map (CMAP) database.

Results

A total of 78 prognosis-related DEGs were identified, of which10 hub genes with higher degree were obtained by PPI analysis. The mRNA expression and protein expression levels of CETN2, MKI67, ARL13B, and SETDB1 were overexpressed in GBM tissues, while the expression levels of CALN1, ELAVL3, ADCY3, SYN2, SLC12A5, and SOD1 were down-regulated in GBM tissues. Additionally, these genes were significantly associated with the prognosis of GBM. We eventually predicted the 10 most vital small molecule drugs, which potentially imitate or reverse GBM carcinogenic status. Cycloserine and 11-deoxy-16,16-dimethylprostaglandin E2 might be considered as potential therapeutic drugs of GBM.

Conclusions

Our study provided 10 key genes for diagnosis, prognosis, and therapy for GBM. These findings might contribute to a better comprehension of molecular mechanisms of GBM development, and provide new perspective for further GBM research. However, specific regulatory mechanism of these genes needed further elaboration.
Appendix
Available only for authorised users
Literature
1.
Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018;140(2):317–28.PubMedCrossRef
2.
3.
Delgado-López P, Corrales-García E. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–71.PubMedCrossRef
4.
Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70(3):412–45.PubMedPubMedCentralCrossRef
5.
Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, et al. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Oncotarget. 2015;6(28):26192–215.PubMedPubMedCentralCrossRef
6.
Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, et al. Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol. 2019;10:42.PubMedPubMedCentralCrossRef
7.
Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau W-C, Ledoux P, et al. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic Acids Res. 2005;33(suppl_1):D562–6.PubMed
8.
Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: mining tens of millions of expression profiles—database and tools update. Nucleic Acids Res. 2006;35(suppl_1):D760–5.PubMedPubMedCentral
9.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.PubMedPubMedCentralCrossRef
10.
Bolstad BM, Irizarry RA, Åstrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185–93.PubMedCrossRef
11.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64.PubMedCrossRef
12.
Zhou G, Soufan O, Ewald J, Hancock RE, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019;47(W1):W234–41.PubMedPubMedCentralCrossRef
13.
14.
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.PubMedPubMedCentralCrossRef
15.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2016;45(D1):D326–68.
16.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef
17.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.PubMedPubMedCentralCrossRef
18.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.PubMedPubMedCentralCrossRef
19.
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507.PubMedCrossRef
20.
Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437–52.PubMedPubMedCentralCrossRef
21.
Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. APJCP. 2017;18(1):3–9.PubMedPubMedCentral
22.
Yang S, Gao K, Li W. Identification of hub genes and pathways in glioblastoma by bioinformatics analysis. Oncol Lett. 2019;17(1):1035–41.PubMed
23.
24.
Taniguchi N, Kizuka Y. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv Cancer Res. 2015;126:11–51.PubMedCrossRef
25.
Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, et al. ER–mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells. EMBO J. 2017;36(11):1493–512.PubMedPubMedCentralCrossRef
26.
Lumeng JY, Wall BA, Wangari-Talbot J, Chen S. Metabotropic glutamate receptors in cancer. Neuropharmacology. 2017;115:193–202.CrossRef
27.
Krasikova YS, Rechkunova N, Maltseva E, Craescu C, Petruseva I, Lavrik O. Influence of centrin 2 on the interaction of nucleotide excision repair factors with damaged DNA. Biochemistry. 2012;77(4):346–53.PubMed
28.
Kamileri I, Karakasilioti I, Garinis GA. Nucleotide excision repair: new tricks with old bricks. Trends Genet. 2012;28(11):566–73.PubMedCrossRef
29.
Huan J, Gao X, Xing L, Qin X, Qian H, Zhou Q, et al. Screening for key genes associated with invasive ductal carcinoma of the breast via microarray data analysis. Genet Mol Res. 2014;13:7919–25.PubMedCrossRef
30.
Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, et al. miR-218 on the genomic loss region of chromosome 4p15. 31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 2011;39(1):13–21.PubMed
31.
Hou Y-Y, Cao W-W, Li L, Li S-P, Liu T, Wan H-Y, et al. MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703. Cancer Lett. 2011;307(2):182–90.PubMedCrossRef
32.
Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, et al. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2016;16(1):398.PubMedPubMedCentralCrossRef
33.
Wang R-j, Li J-w, Bao B-h, Wu H-c, Du Z-h, Su J-l, et al. MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem. 2015;290(14):8938–48.PubMedPubMedCentralCrossRef
34.
Kong J, Wang F, Teodoro G, Cooper L, Moreno CS, Kurc T, et al. High-performance computational analysis of glioblastoma pathology images with database support identifies molecular and survival correlates. Proceedings IEEE Int Conf Bioinformatics Biomed. 2013;2013:229–36.
35.
Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–31.PubMedCrossRef
36.
Casalou C, Faustino A, Silva F, Ferreira IC, Vaqueirinho D, Ferreira A, et al. Arl13b regulates breast cancer cell migration and invasion by controlling integrin-mediated signaling. Cancers. 2019;11(10):1461.PubMedCentralCrossRef
37.
Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev. 2005;15(5):490–5.PubMedCrossRef
38.
Wang G, Long J, Gao Y, Zhang W, Han F, Xu C, et al. SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nat Cell Biol. 2019;21(2):214–25.PubMedPubMedCentralCrossRef
39.
Spyropoulou A, Gargalionis A, Dalagiorgou G, Adamopoulos C, Papavassiliou KA, Lea RW, et al. Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation. NeuroMol Med. 2014;16(1):70–82.CrossRef
40.
Gong L, Bao Q, Hu C, Wang J, Zhou Q, Wei L, et al. Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1. Biochem Biophys Res Commun. 2018;500(2):170–6.CrossRefPubMed
41.
Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384.PubMedPubMedCentralCrossRef
42.
Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Translatl Oncol. 2016;18(11):1062–71.CrossRef
43.
Goni L, Riezu-Boj JI, Milagro FI, Corrales FJ, Ortiz L, Cuervo M, et al. Interaction between an ADCY3 genetic variant and two weight-lowering diets affecting body fatness and body composition outcomes depending on macronutrient distribution: a randomized trial. Nutrients. 2018;10(6):789.PubMedCentralCrossRef
44.
Hong S-H, Goh S-H, Lee SJ, Hwang J-A, Lee J, Choi I-J, et al. Upregulation of adenylate cyclase 3 (ADCY3) increases the tumorigenic potential of cells by activating the CREB pathway. Oncotarget. 2013;4(10):1791–803.PubMedPubMedCentralCrossRef
45.
Labak CM, Wang PY, Arora R, Guda MR, Asuthkar S, Tsung AJ, et al. Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment. Am J Cancer Res. 2016;6(8):1599–608.PubMedPubMedCentral
46.
Kato S, Esumi H, Hirano A, Kato M, Asayama K, Ohama E. Immunohistochemical expression of inducible nitric oxide synthase (iNOS) in human brain tumors: relationships of iNOS to superoxide dismutase (SOD) proteins (SOD1 and SOD2), Ki-67 antigen (MIB-1) and p53 protein. Acta Neuropathol. 2003;105(4):333–40.PubMedCrossRef
47.
Gao Z, Sarsour EH, Kalen AL, Li L, Kumar MG, Goswami PC. Late ROS accumulation and radiosensitivity in SOD1-overexpressing human glioma cells. Free Radical Biol Med. 2008;45(11):1501–9.CrossRef
48.
Li Y, Wang F, Wu L, Zhu M, He G, Chen X, et al. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. Infect Drug Resist. 2019;12:721–31.PubMedPubMedCentralCrossRef
49.
Towndrow KM, Jia Z, Lo HH, Person MD, Monks TJ, Lau SS. 11-Deoxy,16,16-dimethyl prostaglandin E2 induces specific proteins in association with its ability to protect against oxidative stress. Chem Res Toxicol. 2003;16(3):312–9.PubMedCrossRef
50.
Jia Z, Person MD, Dong J, Shen J, Hensley SC, Stevens JL, et al. Grp78 is essential for 11-deoxy-16,16-dimethyl PGE2-mediated cytoprotection in renal epithelial cells. Am J Physiol Renal Physiol. 2004;287(6):F1113–22.PubMedCrossRef
Metadata
Title
Identification of potential biomarkers and candidate small molecule drugs in glioblastoma
Authors
Wei-cheng Lu
Hui Xie
Ce Yuan
Jin-jiang Li
Zhao-yang Li
An-hua Wu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01515-1

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment

Primary research

LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma cell proliferation and resistance to apoptosis by targeting miR-4656/HDAC11 axis

Primary research

Skp2 modulates proliferation, senescence and tumorigenesis of glioma

Primary research

Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma

Primary research

Circ_0072083 interference enhances growth-inhibiting effects of cisplatin in non-small-cell lung cancer cells via miR-545-3p/CBLL1 axis

Primary research

LINC01089 is a tumor-suppressive lncRNA in gastric cancer and it regulates miR-27a-3p/TET1 axis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits